

Lupin launches generic version of Apriso

19 May 2020 | News

It is indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older



Lupin has announced the launch of authorized generic version of Bausch Health's Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.

Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso® had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).